OSU.EDU


Apply Now

pGy2 program
HEMATOLOGY/ONCOLOGY

Residency Programs

Residency Program Director

  • Tracy Wiczer, PharmD, BCOP

    • PGY2 Oncology Residency Program Director, The James Cancer Hospital at The Ohio State University
    • PGY2 Oncology, The James Cancer Hospital at The Ohio State University
    • PGY1, The Jewish Hospital-Mercy Health, Cincinnati, Ohio
    • PharmD, University of Cinicinnati
Previous Year Residents

  • Tracelyn Freeman

    Inpatient/Outpatient BMT and Acute Leukemia, The James Cancer Hospital Solove Research Institute

  • Leylah Azali

    Outpatient Clinical Hematology Specialist, Houston Methodist Hospital

  • Danielle Murphy

    Heme/Onc Cell Therapy Clinical Pharmacy Specialist, Rush University Medical Center, Chicago

  • Kristen Nymberg

    Inpatient/Outpatient GU Medical Oncology Pharmacy Specialist, The James Cancer Hospital Solove Research Institute

  • LeeAnn Geraghty

    Clinical Hematology/Oncology Specialist Pharmacist, Norton Healthcare, Louisville, KY

  • Allison Grana

    Inpatient/Outpatient GU Medical Oncology Clinical Pharmacy Specialist, MD Anderson Cancer Center, Houston, TX

  • Brendan Rasor

    Pharmacist (Outpatient Infusion) Kettering Health Network and the Kettering Cancer Care Pavilion, Dayton OH

  • Justin Tossey

    Inpatient/Outpatient BMT and Acute Leukemia, The James Cancer Hospital Solove Research Institute

About the PGY2 Hematology/ Oncology Residency Program

Purpose

PGY2 pharmacy residency programs build on Doctor of Pharmacy (Pharm.D.) education and PGY1 pharmacy residency programs to contribute to the development of clinical pharmacists in advanced or specialized practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge incorporating both into the provision of patient care that improves medication therapy. Residents who successfully complete an accredited PGY2 pharmacy residency should possess competencies that qualify them for clinical pharmacist and/or faculty positions and position them to be eligible for attainment of board certification in that practice area (when board certification for the practice area exists).

The purpose of the PGY2 Hematology/Oncology residency is to develop specialized knowledge in the pathophysiology and management of patients with hematology and oncology disorders. This is accomplished through core rotations to strengthen hematology and oncology fundamentals as well as elective rotations with the flexibility to meet the individual’s needs.

The program is designed to develop the resident’s clinical expertise and additionally provide opportunities for teaching, research, and quality improvement. Pharmacists completing the residency will be trained as clinical specialists able to excel as an independent practitioner. The goal of the program is to become an integral member of a Hematology/Oncology multidisciplinary team in a large academic setting.

DSC_8758Residency Sites

The Ohio State University Comprehensive Cancer Center – James Cancer Hospital is ranked nationally as one of the top hospitals for cancer care, maintaining an “exceptional” rating – the highest descriptor given by the National Cancer Institute, and is the third largest cancer center in the nation.  Opened in December 2014, with 21 floors spanning 1.1 million square feet, the new James Cancer Hospital and Solove Research Institute revolutionizes the way cancer prevention and care are provided, with over 200 specialized oncologists and cancer researchers working side-by-side to unlock the mysteries of what causes cancer and, using those discoveries, transition from cancer treatment to cancer prevention.

Read More

DSC_8683

This 356-bed adult cancer clinical care facility, including a 36-bed blood and marrow transplant unit, is a member of the National Comprehensive Cancer Network, the National Cancer Institute’s National Clinical Trial Network— notably one of only four centers funded by the NCI to conduct both Phase I and II clinical trials on novel anticancer drugs, achieved Magnet® designation for excellence in patient care, and is fully accredited by the Joint Commission, the American College of Surgeons Common on Cancer and the Foundation for the Accreditation of Cellular Therapy. The center includes six outpatient chemotherapy infusion clinics, dispensing an estimate of over 75,000 doses of chemotherapy annually. The Department of Pharmacy consists of inpatient and outpatient hematology/oncology clinical specialist pharmacists, pain and palliative medicine pharmacists, anti-coagulation pharmacists, cancer informatics pharmacists, medication assistance pharmacists, and Hematology/Oncology specialty practice pharmacy residents.

The James Cancer Hospital at The Ohio State University offers a one-year postgraduate year two (PGY2) ASHP accredited oncology pharmacy residency program. The clinical pharmacy program is designed to align with our subspecialized disease specific model allowing residents the opportunity to train with clinical specialists who are experts in their subspecialty in both inpatient and ambulatory clinic setting. The program allows residents to develop their hematology/oncology knowledge base including cancer treatment, supportive care, and the role of clinical trials in this patient population. Upon completion of the program, the resident will have the skillset necessary to work as a respected member of a multi-disciplinary hematology/oncology patient care team.

KEY ROTATIONS/EXPERIENCES

The resident will complete a combination of rotations and longitudinal experiences designed around the core objectives specified by ASHP in addition to the resident’s interest.

  • Inpatient Acute Leukemia
  • Bone Marrow Transplantation
  • Inpatient Benign Hematology and Lymphoma/Myeloma
  • Inpatient Oncology
  • Outpatient Hematology Clinics
    • Benign Hematology
    • Lymphoma
    • Myeloma
    • BMT and Acute Leukemia
  • Outpatient Oncology Clinics
    • Breast Cancer
    • Gastrointestinal Cancer
    • Gynecologic Cancer
    • Lung Cancer
    • Genitourinary Cancer
    • Head & Neck/Sarcoma
    • Melanoma
    • Neuro-oncology
  • Other Outpatient Clinics
    • Oncology Anticoagulation
    • Clinical Trials Unit
  • Pain and Palliative Care
  • Investigational Drug Service
  • Oncology Administration
  • Informatics
  • Teaching
  • Infectious Disease
  • Medication Safety

Key Preceptors

Learn more about the Hematology/Oncology key preceptors:

Read More

INPATIENT/OUTPATIENT HEMATOLOGY

Jessica Dempsey, PharmD, BCOP
Outpatient Multiple Myeloma

Emily Dotson, PharmD, BCOP
Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma

Bryant Clemons, PharmD
Inpatient/Outpatient BMT and Acute Leukemia

Rebecca Evers, PharmD, BCOP
Outpatient Hematology

Tracelyn Freeman, PharmD
Inpatient/Outpatient BMT and Acute Leukemia

Natalia Gut, PharmD, BCOP
Hematology Float

Lindsay Hazelden, PharmD, BCOP
Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma

Megan Hinkley, PharmD, BCOP
Inpatient/Outpatient BMT and Acute Leukemia

Dan Kendzierski, PharmD, BCOP
Outpatient Hematology/Oncology

Jordan Lundberg, PharmD, BCOP
Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma

Marcin Puto, PharmD, BCOP
Inpatient/Outpatient BMT and Acute Leukemia

Justin Tossey, PharmD
Inpatient/Outpatient BMT and Acute Leukemia

Ally Waller, PharmD, BCOP
Inpatient/Outpatient BMT and Acute Leukemia

Tracy Wiczer, PharmD, BCOP
Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma

INPATIENT/OUTPATIENT ONCOLOGY

Matt Arango, PharmD, BCOP
Outpatient Gastrointestinal Cancer

Brianna Archambeau, PharmD, BCOP
Inpatient Medical Oncology/Outpatient Melanoma

Heather Armbruster, PharmD, BCOP
Inpatient Medical Oncology/Outpatient Melanoma

Michael Berger, PharmD, BCOP
Outpatient Breast Cancer

Stephanie Collins, PharmD, BCOP
Outpatient Breast Cancer

Tyler Dickerson, PharmD, BCOP
Inpatient Medical Oncology/Outpatient Gynecologic Cancers

Eric Fela, PharmD
Inpatient Medical Oncology/Outpatient Gynecologic Cancers

Sarah Hoffman, PharmD, BCOP
Inpatient Medical Oncology/Outpatient Head & Neck Cancer/Sarcoma

Gretchen Junker, PharmD
Oncology Float

Kristen Nymberg, PharmD
Inpatient Medical Oncology/Outpatient Genitourinary Cancers

Josh Reardon, PharmD, BCOP
Outpatient Gastrointestinal Cancer

Tom Schultz, PharmD, BCOP
Inpatient Medical Oncology/Outpatient Head & Neck Cancer/Sarcoma

Michael Smith, PharmD, BCOP
Outpatient Lung Cancer

Greg Samijlenko, PharmD,BCPS, BCOP
Outpatient Neuro-oncology

Craig Vargo, PharmD, BCOP
Outpatient Breast Cancer

Sherry Vogt, PharmD, BCOP
Outpatient Genitourinary Cancers

HEMATOLOGY/ONCOLOGY ANTICOAGULATION

Paige Erdeljac, PharmD, BCACP
Hematology/Oncology Anticoagulation

Stephanie Yager, PharmD
Hematology/Oncology Anticoagulation

PAIN AND PALLIATIVE MEDICINE

Jessica Hirsch, PharmD
Palliative Medicine

Gary Houchard, PharmD
Palliative Medicine

Justin Kullgren, PharmD, CPE
Palliative Medicine

Kyle Quirk, PharmD
Palliative Medicine

Maureen Saphire, PharmD, CGP, CDP
Palliative Medicine

OTHER HEMATOLOGY AND ONCOLOGY PRECEPTORS

Amber Hartman, PharmD
Medication Safety

Naomi Digiantonio, PharmD, BCPS
Clinical Trials Unit

ADMINISTRATION

Hallie Barr, PharmD, BCOP
Pharmacy Manager
Investigational Drugs Services

Janinah Barretto, PharmD, MS
Pharmacy Manager
Oncology Informatics

Mitch Dorn, PharmD, MS
Assistant Director

Morgan Forshay, PharmD, MS, BCPS
Pharmacy Manager, Inpatient Oncology

Sarah Hudson-Disalle, PharmD
Pharmacy Manager
Medication Assistance

Julie Kennerly, PharmD, MS, MHA, BCPS
Assistant Director of Pharmacy
Clinical and Specialty Pharmacy Services

Ben Lopez, PharmD, MS, MHA, BCPS
Director, Enterprise Operations

Stephen Polley, PharmD, MPA, MS, BCPS
Assistant Director

Selected RESIDENT RESEARCH

  • Evaluation of the incidence and risk factors associated with major cardiovascular events in patients receiving acalabrutinib therapy. Azali L
  • Hypomethylating agents with or without venetoclax in adult patients with acute myeloid leukemia. Freeman T
  • Comparison of Fludarabine and Cytarabine with Granulocyte Colony Stimulating Factor vs. Mitoxantrone, Etoposide and Cytarabine as Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia. Murphy D
  • Comparison of subsequent infusion hypersensitivity reactions to paclitaxel using two different infusion strategies. Nymberg K

Benefits and Additional Requirements

Application Deadline:  January 2

Start Date: July 1

Annual Salary – $48,500

Vacation Days – 10 Days

Staffing Requirement – 20 weekends per year

Completion of a Major Research Project

TEACHING OPPORTUNITIES

Download PDF

Quick Links

Contact Us

A Program Offered By:

College of Pharmacy

Wexner Medical Center

©2020 The Ohio State University Pharmacy Residency Program